Induction of antigen-specific humoral tolerance by rAAV-mediated delivery of CTLA4-Ig-antigen fusion molecules

rAAV 介导的 CTLA4-Ig-抗原融合分子递送诱导抗原特异性体液耐受

• 批准号: nhmrc : 477101
• 负责人: Dr Alex Bishop
• 金额: $ 34.97万
• 依托单位: Children's Medical Research Institute
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/induction-antigen-specific-fusion-molecules/76807
• 关键词: Induction; antigen; specific; humoral; tolerance

There are many medical situations where immune suppression is required. Available methods lack specificity and risk infection, drug-related side-effects and cancer. We have discovered a novel way of suppressing immunity such that only unwanted responses are eliminated. This involves virus-mediated delivery of antigen fused to CTLA4-Ig. We plan to test this strategy in the context of gene therapy, to work out how it works and to optimise the approach. Success will have broad health implications.

在许多医疗情况下都需要免疫抑制。现有的方法缺乏特异性，并且存在感染、药物相关副作用和癌症的风险。我们发现了一种抑制免疫力的新方法，可以只消除不需要的反应。这涉及病毒介导的与 CTLA4-Ig 融合的抗原的递送。我们计划在基因治疗的背景下测试这一策略，弄清楚它是如何运作的并优化该方法。成功将对健康产生广泛的影响。